Biotinylated Hsp90β-selective inhibitors

Area of Science:

• Oncology
• Molecular Biology
• Drug Discovery

Background:

• Heat shock protein 90 (Hsp90) is crucial for cancer cell survival by stabilizing client proteins involved in oncogenesis.
• Existing Hsp90 pan inhibitors show significant adverse effects in clinical trials, limiting their therapeutic application.
• Hsp90α isoform inhibition is linked to specific toxicities like cardiotoxicity and ocular toxicity.

Purpose of the Study:

• To investigate potential off-target toxicities of Hsp90β inhibitors.
• To identify cellular proteins interacting with Hsp90β-selective inhibitors.
• To guide the development of safer Hsp90β-selective cancer therapeutics.

Main Methods:

• Synthesis of biotinylated Hsp90β-selective inhibitors with varying tether lengths.
• In vitro validation of synthesized inhibitors.
• Affinity purification experiments to identify interacting proteins.

Main Results:

• Biotinylated Hsp90β-selective inhibitors were successfully synthesized and validated.
• The methodology allows for the identification of proteins interacting with Hsp90β inhibitors.
• This approach provides a foundation for understanding and mitigating off-target effects.

Conclusions:

• The developed Hsp90β-selective inhibitors and methodology are crucial for identifying off-target interactions.
• This research is essential for designing next-generation Hsp90β inhibitors with improved safety profiles.
• The ultimate goal is to develop more effective and less toxic cancer treatments targeting Hsp90β.